Effects of food on the pharmacokinetics of ponatinib in healthy subjects

Journal of Clinical Pharmacy and Therapeutics

Volumn 38, Issue 6, 2013, Pages 440-444

  Narasimhan, N I ^a   Dorer, D J ^a   Niland, K ^a   Haluska, F ^a   Sonnichsen, Daryl ^a,b  

^a ARIAD PHARMACEUTICALS INC   (United States)

^b Sonnichsen Pharmaceutical Associates   (United States)

Author keywords

bioavailability; chemotherapy; haematology; oncology; therapeutics

Indexed keywords

CARBOHYDRATE; FAT; PONATINIB; PROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CALORIC INTAKE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; LIPID DIET; LIQUID CHROMATOGRAPHY; LOW FAT DIET; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY;

BIOAVAILABILITY; CHEMOTHERAPY; HAEMATOLOGY; ONCOLOGY; THERAPEUTICS;

ADULT; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BODY MASS INDEX; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DIETARY FATS; ETHNIC GROUPS; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; HEALTHY VOLUNTEERS; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PYRIDAZINES; SEX CHARACTERISTICS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84886952454     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12082     Document Type: Article

References (13)

1. Hughes T, Deininger M, Hochhaus A, et al,. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 2006; 108: 28-37.
2. Tokarski JS, Newitt JA, Chang CY, et al,. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res, 2006; 66: 5790-5797.
3. Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD,. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer, 2006; 94: 1765-1769.
4. Cortes JE, Kantarjian H, Shah NP, et al,. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med, 2012; 367: 2075-2088.
5. Huang WS, Metcalf CA, Sundaramoorthi R, et al,. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1- y l)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem, 2010; 53: 4701-4719.
6. O'Hare T, Shakespeare WC, Zhu X, et al,. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009; 16: 401-412.
7. Zhou T, Commodore L, Huang WS, et al,. Structural mechanism of the pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des, 2011; 77: 1-11.
8. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al,. A pivotal phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 12-month follow-up of the PACE trial. Blood, 2012; 120:abstract 163.
9. ARIAD Pharmaceuticals, Inc. Ponatinib (Iclusig) prescribing information. Cambridge, MA: ARIAD Pharmaceuticals, Inc., 2012.
10. Novartis Pharmaceuticals Corporation. Imatinib (Gleevec) prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2011.
11. Novartis Pharmaceuticals Corporation. Nilotinib (Tasigna) prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2012.
12. Pfizer Inc. Bosutinib (Bosulif) prescribing information. New York, NY: Pfizer Inc, 2012.
13. Bristol-Myers Squibb. Dasatinib (Sprycel) prescribing information. Princeton, NJ: Bristol-Myers Squibb, 2011.